MedTrace Logo

Open Label, Zonegran (Zonisamide) In Partial Onset Seizures

NCT00215592 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2016-01-08

No results posted yet for this study

Summary

To determine the efficacy and safety of adjunctive open label Zonegran treatment in patients with refractory partial seizures.

Conditions

Interventions

DRUG

Zonegran

Sponsors & Collaborators

  • Eisai Limited

    lead INDUSTRY

Principal Investigators

  • Dr. Tone Bjaaland · Eisai Limited

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-07-31

Countries

  • Austria
  • Denmark
  • France
  • Germany
  • Italy
  • Norway
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215592 on ClinicalTrials.gov